General Information of Drug (ID: DME4LA1)

Drug Name
Tideglusib Drug Info
Synonyms NP-031112; NP-12; NP031112; Tideglusib(NP-031112)
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Osteosarcoma 2B51 Phase 2 [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Cross-matching ID
PubChem CID
11313622
ChEBI ID
CHEMBL3545157
CAS Number
CAS 865854-05-3
TTD Drug ID
DME4LA1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [4]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [5]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [6]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [7]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [8]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [9]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [10]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [11]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [12]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Disulfiram DMCL2OK Alcohol dependence 6C40.2 Approved [3]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [14]
SPI-1005 DM6XFHS Reperfusion injury ND56.Z Approved [3]
PX-12 DMLVHAJ Pancreatic cancer 2C10 Phase 2 [3]
Hexylcarbamoyl fluorouracil DMYNPK8 Solid tumour/cancer 2A00-2F9Z Withdrawn from market [3]
PMID26868298-compound-N3 DMQFUCD Middle East Respiratory Syndrome (MERS) 1D64 Preclinical [3]
GRL0617 DMX9AGF Coronavirus infection 1D92 Preclinical [15]
Isoarnebin 4 DM0B7NO Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
PMID32321856-compound-11a DMN39V6 Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [16]
PMID32321856-compound-11b DM31QEY Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [2]
COVID-19 papain-like proteinase (PL-PRO) TTNHMO8 R1AB_SARS2 (819-2763) Inhibitor [3]

References

1 A Phase II Trial of Tideglusib in Alzheimer's Disease. J Alzheimers Dis. 2015;45(1):75-88.
2 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
3 Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
6 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
7 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
8 Company report (Neurim Pharmaceuticals)
9 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
10 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
11 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
12 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
13 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
14 ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health.
15 Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2021 Jan;11(1):237-245.
16 Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020 Apr 22;eabb4489.